EVER elusive, yet another drug that showed great promise for treatment of Alzheimer's Disease (AD) has failed in late phase studies.
Lundbeck's idalopirdine showed no benefits in Phase III clinical trials, published in JAMA - see jamanetwork.com for the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jan 18